Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 99 years
- Gender
- Only males
Description
This is a master protocol designed to evaluate the safety, tolerability, and maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) and efficacy of AMG 160, in combination with enzalutamide, abiraterone, or the PD1 inhibitor AMG 404 as well as AMG 404 monotherapy, in participants with metas...
This is a master protocol designed to evaluate the safety, tolerability, and maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) and efficacy of AMG 160, in combination with enzalutamide, abiraterone, or the PD1 inhibitor AMG 404 as well as AMG 404 monotherapy, in participants with metastatic castration-resistant prostate cancer (mCRPC).
Tracking Information
- NCT #
- NCT04631601
- Collaborators
- Not Provided
- Investigators
- Study Director: MD Amgen
Get Well Soon